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Abstract
Background: Adamantiades-Behçet’s disease (ABD) is a chronic multisystemic inflammation with unknown
pathophysiology. This disorder is associated with a dysregulation of the cytokine network that hyperactivates
neutrophils and macrophages. In this study, we investigate the modulatory effects of flavonoïd compounds
extracted from Algerian medicinal plant Artemisia herba alba on Th1 and Th2 cytokines and nitric oxide production.
Methods: The modulatory effects of flavonoïds extracted from Artemisia herba alba on cytokines and nitric oxide
production by peripheral blood mononuclear cells isolated from Algerian ABD patients and healthy controls were
respectively measured by means of ELISA assays and Griess modified method.
Results: Our results show that flavonoïds significantly reduce the production of interleukin-12, the key effector of T
helper 1 (Th1) cells and nitric oxide in a dose-dependent manner in Adamantiades-Behçet’s disease. In contrast, the
production of IL-4, the key marker of Th2 cells was increased.
Conclusion: This study suggests that in vitro supplementation with flavonoïds extracted from Artemisia herba alba
could have potential immuno-modulatory effects characterised by a down-regulation and up-regulation of Th1 and
Th2 cytokines, respectively. Moreover, flavonoïds may prevent nitric oxide induced damages.
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Background
Adamantiades-Behest’s disease (ABD) is an inflamma-
tory multisystemic disorder involving mucocutaneous,
ocular, arthritic, vascular and central nervous systems. It
is most prevalent in the Mediterranean countries,
including Algeria, and along the Silk Route. Various fac-
tors have been reported contribute to the development
of the lesions associated to the disease such as, the
genetic susceptibility, environmental factors, anomalies
in the inflammatory responses and immune system dys-
function [1,2].
In response to antigens, mediators such as cytokines
and chemokines are produced by various cell types,
either hematopoietic or non hematopoietic, These med-
iators orchestrate the immune response by recruitment
and activation of different cell types. The involvement of
cytokines and chemokines in ABD pathogenesis is
reflected by the increase of their concentrations in sera
of patients with ABD and some of these mediators cor-
relate with the clinical activity of the disease. Many stu-
dies have indeed reported high sera levels of tumor-
necrosis factor (TNF)-a, TNF receptor, soluble IL-2R
and multiple interleukins (IL-1, IL-6, IL-8, IL-12) [3].
Among them, IL-12 is known to play a major role in
the polarization of T helper (Th)1-type cells and sera
IL-12 and interferon (IFN)-g levels are elevated in ABD
* Correspondence: mdjiji68@hotmail.com
1Laboratoire de Biologie Cellulaire et Moléculaire (LBCM), FSB, USTHB.
Université de Bab-Ezzouar. BP32, 16111. Algiers, Algeria
Full list of author information is available at the end of the article
Messaoudene et al. Journal of Inflammation 2011, 8:35
http://www.journal-inflammation.com/content/8/1/35
© 2011 Messaoudene et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.[4,5]. Moreover, the increase of IL-12 levels in the per-
ipheral blood mononuclear cells (PBMCs) of patients
with ABD have been described [6]. This cytokine is
responsible for the development of a Th-1 type response
and may play a crucial role in the pathogenesis of the
disease [7]. However, other investigators have reported
increased sera levels of Th2-type cytokines, including
IL-4, IL-10, and IL-13 in ABD patients [8], suggesting
disturbed cytokines production in ABD. Such dysregula-
tion in cytokine release contributes to the regulation of
several enzymes such as the inducible nitric oxide (NO)
synthase (iNOS). The function of NO has been deli-
neated in a variety of inflammatory processes. An excess
of NO production or peroxynitrite radical could indeed
cause oxidative damages through its action on mem-
brane lipids, DNA, proteins and lipoproteins [9,10].
These reactions have functional consequences which
m a yb ed e l e t e r i o u s[ 1 1 , 1 2 ] .T h el a r g ea m o u n t so fN O
production have been shown to be correlated with
pathophysiology in a plethora of diseases and inflamma-
tion processes, such as bowel inflammatory disease [13]
and Adamantiades-Behçet’s disease [14]. Consequently,
the development of molecules aimed to prevent the
overproduction of NO constitutes an interesting area of
research of a new treatment of chronic inflammatory
diseases [15-18].
In the absence of curative treatments in ABD, some
patients adopt alternative medicine to avoid the irrever-
sible effects of corticotherapy. For example, Artemisia
herba-alba (Asteraceae) known as “desert wormwood”,
or “Chih” as it is commonly named in Algeria is largely
consumed. Artemisia herba-alba is a plant of the Lamia-
caea family, growing in arid and semi-arid climates and
it is widely used in folk medicine in different countries.
It is characteristic of the steppes and deserts of the Mid-
dle East, North Africa, Spaina n dN o r t hw e s t e r nH i m a -
layas [19]. Artemisia has been a productive genus in the
search for new biologically active compounds. Phyto-
chemical investigations have proven that this genus is
rich in terpenoids, flavonoïds, coumarins, acetylenes,
caffeoylquinic acids and sterols and it was shown that
Artemisia has multiple beneficial bioactivities: anti-
malarial, anti-viral, anti-tumor, anti-pyretic, anti-hemor-
rhagic, anti-coagulant, anti-anginal, anti-oxidant, anti-
hepatitis, anti-ulcerogenic, antispasmodic and anti-com-
plementary activities [20-26].
The flavonoïds detected in Artemisia herba alba show
also a structural diversity starting from common flavo-
noïds (flavones glycosides and favonols) to the methyled
flavonoïds which is very unusual [27,28]. Some benefi-
cial bioactivities of flavonoïds have been proved, such as
antibacterial, anticarcinogenic, antioxidant, antimuta-
genic, anti-inflammatory, activities and immunomodula-
tory activities [29-34]
In the present work was investigated the effect of the
flavonoïds extracted from the medicinal plant A. herba
alba on the production of IL-12 and IL-4 and we exam-
ined nitric oxide production as a marker of the inflam-
matory response in the PBMC of patients with
Adamantiades-Behçet’sd i s e a s e( A B D ) .Artemisia herba
alba may represent an alternative therapy for Algerian
patients with ABD.
Methods
Patients and controls
Samples from Twenty patients (8 men and 12 women)
were obtained from the ophthalmology and internal
medicine service, Bab El Oued Hospital and Algiers
Medicinal University Hospital (Mustapha Bacha),
respectively. Patients with ABD (females and males)
were tested during the clinically active stage. The mean
age of the active stage was 38.43 years (20-58 years) and
the mean duration of the disease was 7.69 years (1-18
years). ABD was diagnosed according to the criteria
defined by the international study group for ABD set up
in 1990 [35]. All ABD patients were showing the major
symptoms including uveitis, aphtosis, articular and neu-
rological manifestations and they had been treated with
colchicine and other oral medication (methylpredniso-
lon, cyclophosphamid). Clinical characteristics of ABD
patients were given in Table 1. Each patient has given a
written informal consent for the study required by the
ethic committee of the national agency of research
development in health (ANDRS) which supported our
project. The healthy controls consisted of 8 males and
12 females (mean age 39.7 years, range 20-59).
Plant materials and flavonoïds extraction
The flowering aerial parts of A. herba alba were col-
lected from Djalfa region (city of south Algeria). The
plant was then identified in the department of botany of
the national institute of agronomy in Algeria. Flavonoïds
were extracted according to the extraction method
described previously by Paris and Nothis [36]. Briefly, 20
g of the pulverized plant material were macerated for 24
hours in methano-containing water (7:3). The filtrate
was evaporated at 40°C to get completely rid of the sol-
vent mixture. The solid extract was then submitted
three times to 50 ml n-butanol to collect the flavonoïds
mixture. The solution was filtrated and evaporated at
40°C and then dissolved in water. The extracts were
kept frozen (-20°C) until used.
PBMC cultures
PBMCs were separated by centrifugation on Ficoll-hypa-
que gradient and washed twice in phosphate-buffered
saline, pH 7.2. Cells were then harvested for test viability
with trypan blue then resuspended in complete medium
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calf serum, 100 units/ml penicillin and 100 μg/ml
streptomycin.
To test cytokines and NO production, PBMC of ABD
patients were treated with different concentrations of
flavonoïds (5, 10, 20, 30, 40 or 50 μg/mL) and incubated
at 37°C and 5% CO2 during 20 hours. Cells were then
harvested for test viability and cultures supernatants
were conserved at -70°C for cytokines and NO
measurements.
For healthy controls and ABD control (before flavo-
noïds treatment), PBMCs were pre-activated with phyto-
haemagglutinin (PHA) (5 μg/mL) in 5% CO2 at 37°C
during 20 hours to mimic the pre-activated stage of
ABD cells.
Cytokine analysis
The concentrations of IL-12 and IL-4 were measured
using enzyme linked immunosorbent assays (ELISA)
according to manufacture’si n s t r u c t i o n s( A m e r s h a m
Pharmacia, England). Supernatants samples were added
to appropriate wells of a microtiter-plate coated with a
specific monoclonal antibody (mAb) against distinct epi-
topes of IL-12 or IL-4. After incubation for 2 hours, 50
μL of anti IL-12 mAb or anti IL-4 mAb conjugated to
horseradish-peroxidase were added. The coloration reac-
tion was read at 540 nm. A standard curve was used to
quantify supernatants levels of IL-12 and IL-4. The low-
est level of sensitivity was 10 pg/mL for IL-12 and 5 pg/
mL for IL-4 of the cytokine.
NO production by PBMCs
PBMCs of patients and NCs were cultured at 5 × 10
6
cells/uL (100 uL/well) with 100 uL of flavonoïds extract
(5, 10, 20, 30, 40 or 50 μg/mL) in 96-well microtiter-
plates in a humidified incubator at 37°C and 5% CO2
for 20 hours. Then NO production was assessed by the
determination of the final products of NO oxidation.
After reduction of nitrates (NO
-
3) by nitrate reductase
containing Pseudomonas oleoveorans Bacteria (ATCC,
8062) containing nitrate reductase, total nitrite (nitrite
NO
-
2+n i t r a t eN O
-
3) was determined with the
spectrophotometrically Griess reaction as described by
Amri et al [37]. Griess reagent 2% p-amminobenzene
sulphanamide in 5% phosphoric acid and 0.2% N (1-
naphhtiyl) ethylene diamine (dihydrochlorid) was added
to the sample. The mixture was incubated for 10 min-
utes at room temperature and the absorbance at 543
nm was read by spectrophotometer. The concentration
was determined with reference to a sodium nitrites
NaNO2 standard (0-200 μmol/mL) curve. Results were
expressed as μMo fn i t r i t e si ns u p e r n a t a n t so fP B M C
cultures.
Statistical analysis
Results were expressed as the mean ± standard devia-
tion. Statistical differences were assessed using one-way
ANOVA with posthoc test of the means according to
Tukey’s method. In single mean comparisons, Student’s
t-test was used to test the data and considered statisti-
cally significant for P values < 0.05. Results and graphics
were performed with STATISTCA v. 5 software under
windows.
Results
In vitro production of cytokine during the active stage of
ABD
To quantify the spontaneous production of IL-12, IL-4
and NO during the active stage, we measured their
levels in cultures supernatants of PBMC of ABD
patients compared with NCs. As shown in Figure 1A,
IL-12 levels in ABD patients were higher than in NCs:
1134.02 ± 83.70 versus 583.02 ± 98.44 pg/mL, p < 0.05.
The stimulation with flavonoïds showed an increased
level of IL-12 in both ABD patients and NCs (1358.63 ±
118.41 versus 1143.27 ± 104.73 pg/mL, respectively).
However, we did not observe any significant difference
(P > 0.05). In the absence of PHA stimulation, PBMC
from ABD patients showed similar level of IL-12
(1134.03 ± 83.69) compared to PBMC from controls
after stimulation with PHA (p < 0.85). This result
prompted us to use for the same plant extract treatment
experiment the preactivated PBMC from controls and
those from ABD patients without activation with PHA.
Table 1 Characteristics of active stage of Adamantiades-Behçet’s disease patients (number mean ± standard deviation,
percentage)
Sex (M/F) 8/12
Age at disease onset (mean years +SD) 34 ± 10
Follow-up duration (years) 7.69 ± 8.5 (1-18)
Uveitis 7/20 (35%)
Aphtosis 6/20 (30%)
Articular symptoms 4/20 (20%)
NeuroBehçet 3/20(15%)
Treatments Colchicine, methylprednisolon, cyclophosphamid
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Figure 1 Cytokines and nitric oxide concentration in PBMC supernatants cultures.P B M C( 5×1 0
6 cells/ml) of patients with ABD and
healthy controls were cultured with or without 5 μg/ml phytohemagglutnin (PHA) for 20 h. Supernatants were collected and the production
level of lL-12 (A) and IL-4 (B) was determined by a sandwich ELISA. Values shown are mean ± S.D.*p < 0.001 was significantly different from the
control value. C. Concentration of nitric oxide in the supernatants of culture of PBMC from patients with Adamantiades-Behçet’s disease and
healthy controls. Cells were treated with 5 μg/mL of PHA. Supernatants were collected after 20 h and the nitrite level was determined by
modified Griess reaction. The data represent the mean ± S.D. of cultures. *p < 0.05. NO levels were significantly different from the control values.
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ABD patients and normal control’s indicated different
profiles according to the disease evolution (Figure 1B).
Indeed, during the active phase, we observed a higher
spontaneous production in ABD patients’ PBMC culture
supernatants in comparison to the healthy controls (63.1
± 37 versus 39.7 ± 13.1 pg/mL, P < 0.05). PHA induced
a significant increase in the cytokine production in all
groups tested. However, IL-4 levels in PBMCs superna-
tants, after stimulation with PHA (5 μg/mL) were signif-
icantly higher in ABD patients compared to the controls
(241.8 ± 33.5 versus 131.3 ± 12.6 pg/mL, p < 0.001)
(Figure 1B). In contrast, the preactivated PBMC from
controls showed a significant modification in IL-4 pro-
duction after treatment with PHA at 5 μg/mL compared
to ABD patients without stimulation (p < 0.001).
In vitro production of NO during the active stage of ABD
NO measurement in culture supernatants showed that
the spontaneous production was higher in ABD PBMC
cultures compared to NCs (65.39 ± 15.56 versus 22.84 ±
1.40 μM, p < 0.001). Further, NO levels increased signif-
icantly in all culture supernatants after treatment with
PHA (P < 0.05). We noticed that NO levels in treated
PBMC cultures from ABD was higher than in healthy
controls (118.48 ± 15.49 versus 78.31 ± 13.41 μM, p <
0.001) (Figure 1C). The preactivated PBMC cultures
from NCs treated with PHA did not show any signifi-
cant difference compared to those from ABD patients
without prestimulation (p = 0.054).
Flavonoïds did not affect cells viability
To assess if there is any cytotoxic effect of flavonoïds,
we tested cell viability before and after PHA treatment.
Viability of cells was about 90% before and about 70%
after experiments with no differences between flavo-
noïds-treated and untreated control cells. So flavonoïds
were not cytotoxic which is consistent with the previous
observations [38].
Flavonoïds modulate IL-12 and IL-4 production in PBMCs
of ABD patients and NCs
To further confirm the enhancement of the production
of the cytokines production by flavonoïds and their apti-
tude to respond to the PHA preactivated PBMC in
healthy controls, flavonoïds were added at different
doses 5, 10, 20, 30, 40 or 50 μg/mL for 20 hours. The
contents of the wells were centrifuged and kept frozen
until analyzed. We observed that flavonoïds did not
reduce the IL-12 production in the PBMC stimulation
by PHA in NCs (Figure 2). No reversal effects were
noticed at any flavonoïd concentrations used. (808.57 ±
123.12 pg/mL, 5 μg/mL of flavonoïds) and (1194.87 ±
53.56 pg/mL, 50 μg/mL of flavonoïds) compared to
control values in the absence of flavonoïds (599.47 ±
83.56 pg/mL).
To test if flavonoïds could induce cytokines modula-
tion in patients without PHA, PBMC from patients were
cultured in the presence of different concentrations of
flavonoïds (5-50 μg/mL). We observed a significant
decrease in IL-12 production in a dose-dependent man-
ner (p < 0.001). Interestingly, we have observed that the
pre-treatment by flavonoïds inhibited IL-12 production
(1048.89 ± 128.93 pg/mL with 10 μg/mL of flavonoïds)
and (778.63 ± 115.21 pg/mL with 50 μg/mL of flavo-
noïds) compared to control values (1221.42 ± 36.01 pg/
mL). (Figure 3). There is no statistical differences
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Figure 2 Effect of flavonoïds on IL-12 production by PHA pre-
activated peripheral blood mononuclear cells. After washing
with medium, various concentrations of flavonoïds (5 -50 μg/mL)
was added for a period of 20 h. Supernatants were collected and
the levels of IL-12 were determined by ELISA. The data represent
the mean ± S.D. of triplicate cultures. *p < 0.001, IL-12 levels are
significantly different from the control value.
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Figure 3 Effect of various concentrations of flavonoïds
extracted from A. herba alba on IL-12 production in PBMC (5 ×
10
6 cells/mL) of patients with ABD. Presence of cytokines in
supernatants was assessed by ELISA. Results are mean ± SD of
separate experiments performed in triplicate. *p < 0.05 were
significantly different from the control values.
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IL-12 production in PBMC from ABD patients.
Similarly, the amounts of IL-4 released into superna-
tants of PBMC from controls subjects after pre-stimula-
tion with PHA were determined by ELISA (Figure 4).
Treatment of PBMC by different concentrations of fla-
vonoïds inhibited IL-4 production (73.26 ± 10 pg/mL,
30 μg/mL of flavonoïds) and (89.90 ± 13.25 pg/mL, 50
μg/mL of flavonoïds) compared to the control values in
the absence of flavonoïds (55.87 ± 7.98 pg/mL).
In PBMC from ABD patients, flavonoïds stimulated
IL-4 production in a dose-dependent manner and at sig-
nificantly greater levels compared to the controls (Figure
5). The highest concentration tested (50 μg/mL)
exhibited an increased bioactivity. Treatment of flavo-
noïds induced IL-4 production (1.116 ± 0.207 pg/mL
with 10 μg/mL of flavonoïds) and (0.24 ± 0.060 pg/mL
with 40 μg/mL of flavonoïds) compared to the control
values in the absence of flavonoïds (55. 87 ± 7.98) (Fig-
ure 5).
Flavonoïds inhibited nitric oxide production in PBMC
from ABD patients
Next, we examined the effect of flavonoïds on NO pro-
duction in PBMC from controls subjects stimulated by
PHA were tested. NO levels were measured by Griess
modified method. We observed that the treatment did
not modulate NO production. As shown in Figure 6, fla-
vonoïds had no statistically significant effect (19.21 ±
2.61 μMw i t h1 0μg/mL of flavonoïds and 16.36 ± 4.25
μMw i t h5 0μg/mL of flavonoïds). The control values in
the absence of flavonoïds being 21.03 ± 4.31 μM.
We then tested the inhibitory effect of flavonoïds on
NO production in PBMC from ABD patients (Figure 7).
Interestingly, we observed that the treatment with flavo-
noïds during 20 h reduced the NO concentration in all
cultures supernatants (p < 0.05). This inhibitory effect
was in dose-dependent manner (10 μg/mL and 50 μg/
mL). The corresponding nitrite concentrations assessed
were respectively: 36.13 ± 5.22 μM and 20.47 ± 3.85 μM
Discussion
It is currently recognized that Th cells may be divided
i n t os e v e r a lf u n c t i o n a ls u b classes, Th-1, Th-2, Treg,
Th17 cells, based on the production profile of cytokines
and their effects on cell mediated and humoral immu-
nity. Th-1 cells produce IL-12, IFN-g and enhance cell-
mediated immunity. Th-1 cells also can inhibit cell-
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Figure 4 E f f e c to ff l a v o n o ï d so nI L - 4p r o d u c t i o ni nP H A -
stimulated PBMC of healthy controls. Amounts of IL-4 were
measured by ELISA. PBMC (5 × 10
6 cells/mL) were cultured for 20 h
in the absence or presence of flavonoïds after stimulation with PHA
(5 μg/mL). Data represent the mean ± SD of three independent
experiments in each sample compared to controls value and PHA-
treated alone value (ANOVA with post-hoc test).
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Figure 5 Effect of flavonoïds extract on IL-4 (pg/mL)
production in PBMC of ABD patients (n = 20). Cells (5 × 10
6
cells/mL) were treated with different concentrations (5, 10,20,30,40
and 50 μg/mL) of flavonoïds during 20 h. Presence of cytokines in
supernatants were measured by ELISA test. Results are mean ± SD
of seven separate experiments performed in triplicate. *p < 0.05 IL-4
levels were significantly different from the control value.
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Figure 6 Effect of flavonoïds on nitric oxide production in
PHA-stimulated PBMC of healthy controls. PBMC (5 × 10
6 cells/
mL) were stimulated with PHA then cultured with or without
flavonoïds (5, 10, 30, 40 and 50 μg/mL). The cell-free supernatants
were collected and NO concentration was determined by Griess
modified method. The data represents the mean ± S.D. of triplicate
cultures.* p < 0.05 NO rates was significantly different from the
control value (ANOVA with post-hoc test).
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showed a significant increase of IL12 levels in superna-
tant of PBMC culture from ABD patients. IL-12 is an
immunoregulatory cytokine regulating cell-mediated
immune response by inducing the differentiation of
uncommitted CD4 Th cells towards type 1 phenotype
and a potent cofactor for stimulating the proliferation of
differentiated Th1 cells and IFN-g synthesis [39]. In our
study, we confirmed that IL-12 production by PBMC is
significantly higher in ABD patients compared to
healthy controls suggesting that IL-12 is involved in the
pathogenesis of ABD.
Moreover, Th-2 cells produce IL-4, IL-5 and IL-13
and upregulate humoral immunity [40]. In the current
study, higher concentrations of IL-4 were also observed
in ABD patients. This Th-2 derived cytokine is primarily
involved in the activation of B cells, the promotion of
growth and the survival of T cells, the inhibition of
macrophage and the activation and suppression of Th-1
cells. Recent studies have showed that IL-4 and IL-12
play a significant role in the regulation of the immune
responses by their reciprocal antagonistic mechanisms.
We found that the concentration of nitric oxide in the
PBMC supernatant were significantly elevated in ABD
patients compared to the healthy controls. Here, we
postulated that NO could play an important role in the
inflammatory process associated with Adamantiades-
Behçet’s disease [41]. Several studies have suggested that
the overexpression of either inducible NO and proin-
flammatory cytokines might be intimately involved in
the pathogenesis and the evolution of ABD [12,42]. An
increase in the concentration of NO during the ABD
was reported in several studies and this in both the sera
of patients [43] and also in the synovial liquid [44]. The
presence of NO was also observed in uveitis associated
with ABD in particular in the aqueous humour [45,46].
The increase of NO levels in all cases was correlated
with the active stage of the ABD.
Stimulation of PBMC cultures from ABD patients with
PHA induced an increase of IL-12, IL-4 and NO pro-
duction. We suggest that the increase of the IL-4 levels
in ABD patients after PHA stimulation is probably
related to the presence of some factors induced by PHA
in PBMC cultures acting on Th-2 cells subset. This pur-
pose remains to be clarified in adequate experiment
model. Regarding to the comparison between the pro-
duction of IL-4 by PHA in healthy controls and ABD
patients, the difference observed is probably in relation
with the difference in the initial activation level of
PBMC state in the two groups of subjects.
Moreover, the increase IL-12 levels after stimulation
with PHA on PBMC from ABD patients is related to
the production of IFN-g by Th1 cells. This is consistent
with the fact that IFN-g is known to strongly activate
the monocyte/Macrophage system which is the major
source of IL-12. Several studies have reported that NO
is upregulated by IFN-g. Recently, our group showed the
pivotal role of IFN-g in pathophysiology of ABD particu-
larly via the NO pathway [46].
There is an increasing interest in herbal medications
especially for diseases like ABD [47,48]. The present study
demonstrates that flavonoïds extracts from A. herba alba
highly inhibited the production of the proinflammatory
cytokine IL-12 in ABD patients PBMC. The mechanism
involved remains to be clarified. Furthermore, in our study
we reported that the inhibitory effect on IL-12 production
was not due to the toxicity of flavonoïds on PBMC. In
fact, in our culture system the use of a high flavonoïds
concentration at 50 pg/ml after 20 h incubation yielded
almost 70% viable cells. It has been shown that increased
IL-12 levels and Th1 cytokines did occur in patients with
ABD and have been associated with the pathogenesis.
In contrast to IL-12, we found that flavonoïds pro-
moted a significant increase in IL-4 produced. IL-4 is
one of the Th-2 cytokines which has been associated
with an improvement in the inflammatory diseases [49].
In the study reported by Koteswara Rao et al., [50], fla-
vonoïds have been shown to inhibit extensively the
proinflammatory cytokines like TNF- a,I L - 1 2i na
dose-dependent manner. These authors suggested that
flavonoïds mediate differentiation from Th-1 to Th-2
cell types and our results are consistent with this study.
We also suggest the role of other cytokines or immu-
noregulatory mediators in the differential regulation of
IL-4 (upregulated) and IL-12 (downregulated). These
suggestions remain to be clarified in an adequate experi-
mental model. However, it is possible that the inhibition
of IL-12 production may be partially mediated by the
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Figure 7 Effect of different concentration of flavonoïds on
nitric oxide production by PBMC in patients with ABD.
Flavonoïds extracts from A. herba alba are used at the indicated
concentrations and compared to the controls. Supernatants were
collected to determine the amount of NO. The data represents the
mean ± S.D. of triplicate cultures. *p < 0.05 was significantly
different from the control value (absence of flavonoïds).
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Page 7 of 9action of flavonoids through IL-4 induction as both IL-4
and IL-12 have shown to have antagonism effects. IL-4
exerts strong inhibition on Th1-mediated inflammatory
processes involving the regulation of the synthesis of
inflammatory cytokines (IL-2 TNF-a,I L - 1 b) and che-
mokines (CXCL8, CXCL10, CCL2). The effect of flavo-
noïds on cytokine modulation constitutes a very exciting
finding for their possible therapeutic applications.
For the role of NO, we suggest that flavonoïds regu-
late not only the balance Th1/Th2 towards Th-2 but
also NO production. The results presented here show
that flavonoïds isolated from A. herba halba, affect also
NO production in PBMC isolated from patients with
ABD in a dose-dependent manner. The inhibitory activ-
ity could be resulted from the inhibition of iNOS
expression and/or its activity.
Conclusion
We report here the evidence that the Th-1 cytokines
(IL-12) and NO are involved in the pathogenesis of
ABD. Our limited follow-up study also suggests that fla-
v o n o ï d se x t r a c t sf r o mA .herba alba have an effect on
the inhibition and the stimulation of the production of
IL-12 and of IL-4, respectively. This constitutes a way to
switch the immune response from Th-1 to Th2. Further
investigations will focus on the assessment of the biolo-
gical activity of this extract in vivo and on the chemical
identification of the active components responsible for
the anti-inflammatory activity. The knowledge of the
role of flavonoïds in the immunomodulatory mechan-
isms in ABD is a promising area for the development of
new natural’s agents for the treatment of the disease
and other immune-mediated diseases.
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